Lung Therapeutics lungtx.com


Public list: BIO 2016 (619) Pharma Startups (4733)

Lung Therapeutics is a corporation that leverages NIH validated and funded programs to develop first in class therapies for niche indications in lung injury and disease. Lung Therapeutics is a spinout from UT Health Northeast and takes advantage of more than 25 years of research in lung disease. Lung Therapeutics pursues indications for which there is currently no effective therapeutic option.

Lung Therapeutics is a corporation that leverages NIH validated and funded programs to develop first in class therapies for niche indications in lung injury and disease. Lung Therapeutics is a spinout from UT Health Northeast and takes advantage of m...Show all

Company (Alive / Active)

Phone: 737-802-1973

Fax:

1515 S. Capital of Texas Hwy
Suite 402
Austin, 78746
Texas, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Lung Therapeutics $19.1M Mar 8, 2016
See all 3 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Lung Therapeutics Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 6 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

Anthera Pharmaceuticals

Hayward, California, United States
IPO / Went publicAnthera Pharmaceuticals is a pharmaceutical development company focused on the development and advancement of promising clinical products for the treatment of serious inflammatory diseases. Anthera's lead products have the potential to address a variety of inflammatory diseases including: acute lung injury, acute respiratory distress syndrome, acute chest syndrome, acute coronary syndrome, atherosclerosis, chronic obstructive pulmonary disease and psoriasis.Login to see details

REVOTAR Biopharmaceuticals

Germany
Alive / ActiveRevotar develops anti-inflammatory drugs for inflammatory indications such as psoriasis, acute lung injury (ALI) and chronic obstructive pulmonary disease (COPD).Login to see details
See all 3 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)